02 - April - 2010

Follow-up studies, autonomously performed by independent researchers, further established that PlGF is a disease-candidate gene in spontaneously developing cancer models, induced by onco-transgene expression or carcinogen-exposure, and that anti-PlGF antibody delivery slows down cancer in these models by inhibiting or altering the tumor vasculature - these findings are reported in a joint Cell publication, co-authored by numerous experts in the field. Cell, Volume 141, Issue 1, 178-190, 2 April 2010.

Furthermore, two additional abstracts, to be presented at the upcoming AACR meeting April 17-21 in Washington DC, confirmed the therapeutic potential of anti-PlGF; one of these studies was performed by the biopharma company Roche, who is currently conducting clinical phase I/II trials to test the therapeutic potential of anti-PlGF in cancer patients, while another study was performed independently by Steinwei Biotech, China – see links to abstracts below this message.

AACR 101st Annual Meeting 2010 : April 17-21, 2010 – Walter E. Washington Convention Center - Washington

Xu et al : P16, a novel monoclonal antibody specifically recognizing human placental growth factor (PLGF), blocks PLGF-VEGFR1 interaction in vitro and inhibits angiogenesis and tumor growth in vivo AACR Abstract Presentation Apr 19, 2010, 2:00 PM - 5:00 PM
Read full abstract here

Rizzo et al : RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo AACR Abstract Presentation Apr 19, 2010, 9:00 AM - 12:00 PM
Read full abstract here